General Category > Shares
Aspen Pharmacare
jaDEB:
Why did we miss this one?
??? ???
Patrick:
--- Quote from: jaDEB on June 28, 2013, 10:38:14 am ---Why did we miss this one?
??? ???
--- End quote ---
Haha funny enough we didn't. I just posted in the long term thread reminding about my choice :D
Orca I'm breathing down your neck in the contest!
Patrick:
--- Quote ---(Reuters) - Aspen Pharmacare said on Thursday that it would acquire drugs and a plant from U.S. firm Merck in a $1 billion deal that bolsters its presence in Europe, Latin America and Asia.
Africa's biggest maker of generic drugs said it would buy an active pharmaceutical ingredient (API) business located in the Netherlands and a portfolio of 11 drug brands from Merck.
Aspen said the deal was subject to the approval of various competition authorities and the South African Reserve Bank.
Last week, Aspen said it would acquire the Arixtra and Fraxiparine/Fraxodi brands of thrombosis drugs from GlaxoSMithKline, except in China, Pakistan and India, a deal that could also be worth $1 billion.
Shares in Aspen, rose more than 1 percent on the news, outperforming a 0.7 percent decline in Johannesburg's benchmark Top-40 index.
--- End quote ---
http://www.reuters.com/article/2013/06/27/us-aspen-merck-idUSBRE95Q0H520130627
Orca:
--- Quote from: Patrick on June 28, 2013, 10:43:49 am ---
--- Quote from: jaDEB on June 28, 2013, 10:38:14 am ---Why did we miss this one?
??? ???
--- End quote ---
Haha funny enough we didn't. I just posted in the long term thread reminding about my choice :D
Orca I'm breathing down your neck in the contest!
--- End quote ---
Yea. But I'll be eating your dust soon. CML just cannot go any higher at this stage.
Moonraker:
Hoping for a bounce back soon, now that Glaxo has completed their partial sale of APN stock.
GSK completes sale of Aspen shares
But what about that LT trade of 9,940,000 @250 ??
In accordance with section 122(3)(b) of the Companies Act, No. 71 of 2008 (“the Act”), and section
3.83(b) of the JSE Listings Requirements, holders of ordinary shares in the Company are advised
that:
Glaxo Group Limited (“GSK”), has disposed of Aspen Holdings ordinary shares, such that its
beneficial interests in Aspen Holdings now amounts to 12.4% of the total number of shares in
issue.
Last 10 Trades of the day
Date PDT Price Volume
20/11 17:50 LT 25000 9,940,000
20/11 17:48 OP 25743 308
20/11 17:45 OP 25716 79,122
20/11 17:44 OP 25692 1,000,000
20/11 17:37 OP 25652 350,000
20/11 17:00 OCP 25700 0
20/11 17:00 AT 25700 138,022
20/11 16:49 AT 25699 100
20/11 16:49 AT 25699 466
20/11 16:49 AT 25699 89
Navigation
[0] Message Index
[#] Next page
Go to full version